It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
As one of the most malignant cancer types, hepatocellular carcinoma (HCC) is highly invasive and capable of metastasizing to distant organs. Intermedin (IMD), an endogenous peptide belonging to the calcitonin family, has been suggested playing important roles in cancer cell survival and invasion, including in HCC. However, how IMD affects the behavior of HCC cells and the underlying mechanisms have not been fully elucidated. Here, we show that IMD maintains an important homeostatic state by activating the ERK1/2-EGR1 (early growth response 1) signaling cascade, through which HCC cells acquire a highly invasive ability via significantly enhanced filopodia formation. The inhibition of IMD blocks the phosphorylation of ERK1/2, resulting in EGR1 downregulation and endoplasmic reticulum stress (ER) stress, which is evidenced by the upregulation of ER stress marker DDIT3 (DNA damage-inducible transcript 3). The high level of DDIT3 induces HCC cells into an ER-stress related apoptotic pathway. Along with our previous finding that IMD plays critical roles in the vascular remodeling process that improves tumor blood perfusion, IMD may facilitate the acquisition of increased invasive abilities and a survival benefit by HCC cells, and it is easier for HCC cells to obtain blood supply via the vascular remodeling activities of IMD. According to these results, blockade of IMD activity may have therapeutic potential in the treatment of HCC.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Sichuan University, Department of Intensive Care Unit of Gynecology and Obstetrics, West China Second University Hospital, Chengdu, People’s Republic of China (GRID:grid.13291.38) (ISNI:0000 0001 0807 1581)
2 Capital Medical University, Liver Transplantation Center, Beijing Friendship Hospital, Beijing, People’s Republic of China (GRID:grid.24696.3f) (ISNI:0000 0004 0369 153X)
3 Sichuan University and Collaborative Innovation Center of Biotherapy, Department of Critical Care Medicine, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Chengdu, People’s Republic of China (GRID:grid.13291.38) (ISNI:0000 0001 0807 1581)
4 Sichuan University, Department of Liver Surgery, West China Hospital, Chengdu, People’s Republic of China (GRID:grid.13291.38) (ISNI:0000 0001 0807 1581)